Progress in Neurotherapeutics and Neuropsychopharmacology 2007
Progress in Neurotherapeutics and Neuropsychopharmacology · 2007
DOI: 10.1017/s1748232106000024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Progress in Neurotherapeutics and Neuropsychopharmacology, 2007. Verfasst von Jeffrey L. Cummings. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
There continues to be progress in neurotherapeutics and neuropsychopharmacology with each advancing year. Production of new molecular entities (NME's) remains small, but advances are being made in repurposing agents and extending their indications, obtaining more safety and tolerability data in long term and extension studies, introducing novel trial methodologies that provide insight into how to best to conduct trials and how best to treat diseases, and developing new formulations that improve adherence and decrease the barriers to patient compliance. Advances in how to test potential disease-modifying agents in patients with progressive neurological illnesses is advancing. Promising biomarkers have been identified in some neurological diseases.
Zitieren
APA
Cummings, J. L. (2007). Progress in Neurotherapeutics and Neuropsychopharmacology 2007. Progress in Neurotherapeutics and Neuropsychopharmacology. https://doi.org/10.1017/s1748232106000024
Vancouver
Cummings JL. Progress in Neurotherapeutics and Neuropsychopharmacology 2007. Progress in Neurotherapeutics and Neuropsychopharmacology. 2007. doi:10.1017/s1748232106000024
BibTeX
@article{Cummings2007,
author = {Cummings, Jeffrey L.},
title = {Progress in Neurotherapeutics and Neuropsychopharmacology 2007},
journal = {Progress in Neurotherapeutics and Neuropsychopharmacology},
year = {2007},
doi = {10.1017/s1748232106000024}
}
EUVIMED